Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | EED | O75530 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 1.00 |
| ▸ | CBR1 | P16152 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 6/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Wedelolactone SCHEMBL30669739 | 1.00 | MEN1 (1.00) | MEN1KMT2ARECQLBLMSLC22A2 | |
| Wedelolactone SCHEMBL29802384 | 1.00 | MEN1 (1.00) | MEN1KMT2ARECQLBLMSLC22A2 | |
| SCHEMBL14492102 | 0.91 | MEN1 (0.83) | MEN1KMT2ARECQLBLMSLC22A2 | |
| SCHEMBL27349604 | 0.88 | MEN1 (0.79) | MEN1KMT2ARECQLBLMSLC22A2 | |
| Demethylwedelolactone SCHEMBL31146849 | 0.84 | MEN1 (0.72) | MEN1KMT2ARECQLBLMSLC22A2 | |
| Demethylwedelolactone SCHEMBL3364302 | 0.84 | MEN1 (0.72) | MEN1KMT2ARECQLBLMSLC22A2 | |
| SCHEMBL30321460 | 0.83 | MEN1 (0.71) | MEN1KMT2ARECQLBLMSLC22A2 | |
| SCHEMBL30335047 | 0.83 | MEN1 (0.71) | MEN1KMT2ARECQLBLMSLC22A2 | |
| SCHEMBL30015278 | 0.80 | MGAM (0.74) | MEN1KMT2ARECQLBLMSLC22A2 | |
| SCHEMBL27857524 | 0.80 | MGAM (0.74) | MEN1KMT2ARECQLBLMSLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122004256-A | Plant immunity regulator for preventing jackfruit cracking and use method thereof | 海南省农业科学院热带果树研究所 | 2026-05-12 | — | — | CN | claimed |
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| EP-3946437-B1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | H LEE MOFFITT CANCER CT & RES (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | PLUTO INC (KR) | 2025-10-30 | — | — | US | claimed |
| CN-120078851-A | Traditional Chinese medicine formula with cough relieving and phlegm resolving functions and preparation method and application thereof | 戴政德 | 2025-06-03 | — | — | CN | claimed |
| US-20250170166-A1 | HYALURONIC ACID HYDROGEL FORMULATION COMPRISING PHYTOESTROGEN FOR THE TREATMENT OF VAGINAL ATROPHY AND VAGINAL REJUVENATION AND PRODUCTION METHOD THEREOF | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2025-05-29 | — | — | US | claimed |
| CN-120037393-A | Wedelolactone-loaded exosome and application thereof in preparation of medicines for preventing and treating sepsis | 中国人民解放军空军军医大学 | 2025-05-27 | — | — | CN | claimed |
| WO-2025049966-A9 | METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-04-17 | — | — | WO | claimed |
| CN-119770504-A | Pharmaceutical composition for preventing and treating AD and application thereof | 黑龙江中医药大学 | 2025-04-08 | — | — | CN | claimed |
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| CN-1810809-A | Coumarether compound and new use of its composition | SHANGHAI ANPU BIOLOG SCI TECH (CN) | 2006-08-02 | — | — | CN | claimed |
| CN-1566116-A | Process for preparing wedelia lactone and application thereof | UNIV BEIJING (CN) | 2005-01-19 | — | — | CN | claimed |
| US-6552071-B2 | Wedelolactone and its synthesis for treating neurodegenerative diseases | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2003-04-22 | — | — | US | claimed |
| EP-1237550-A2 | METHODS FOR TREATING CELL DEATH DISEASES AND INFLAMMATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-09-11 | — | — | EP | claimed |
| US-20020049251-A1 | Methods for treating cell death diseases and inflammation | HARVARD COLLEGE, PRESIDENT AND FELLOWS | 2002-04-25 | — | — | US | claimed |
| WO-2001041709-A2 | METHODS FOR TREATING CELL DEATH DISEASES AND INFLAMMATION | PRESIDENT AND FELLOWS OF HARWARD COLLEGE (US) | 2001-06-14 | — | — | WO | claimed |
| US-5559146-A | REGULATION OF SKIN PIGMENTATION, WEDELOLACTONES | SABLON LEWIS E (FR) | 1996-09-24 | — | — | US | claimed |
| EP-0595988-B1 | COSMETIC COMPOSITIONS COMPRISING AN EXTRACT OF ECLIPTA ALBA | SABLON LOUIS EMMANUEL (FR) | 1995-12-27 | — | — | EP | claimed |
| EP-0595988-A1 | COSMETIC COMPOSITIONS COMPRISING AN EXTRACT OF ECLIPTA ALBA. | SABLON LOUIS EMMANUEL (FR) | 1994-05-11 | — | — | EP | claimed |
| WO-1993001796-A1 | COSMETIC COMPOSITIONS COMPRISING AN EXTRACT OF ECLIPTA ALBA | SABLON LOUIS EMMANUEL (FR) | 1993-02-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | MYOF, ALOX5, MYLK2 | MEN1 4605/4885KMT2A 2276/4885RECQL 3344/4885 |
| US-20020049251-A1 | Methods for treating cell death diseases and inflammation | CASP3, CASP9, CASP2 | MEN1 3764/4885KMT2A 4228/4885RECQL 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.